Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00094874
Other study ID # 801685
Secondary ID
Status Recruiting
Phase Phase 3
First received October 27, 2004
Last updated June 23, 2005
Start date September 2004
Est. completion date September 2005

Study information

Verified date October 2004
Source The Mary Elizabeth Groff Surgical Medical Research and Education Charitable Trust
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Acupuncture is a form of Chinese medicine that has been in existence for more than a thousand years. This clinical trial performs two types of acupuncture on traditional 'bladder' points to determine if one type demonstrates improvement over the other. In the first type needles stimulate acupuncture points on the skin, and in the second type the needles penetrate through the skin similar to how acupuncture is usually performed. The technique is done through shields so that people will not know what type of acupuncture they receive.

Patients must have at least moderately severe disease as determined by a urologist. They must be willing not to change their medical regimen for the duration of the trial. Patients will receive twelve treatments over six to twelve weeks. They will be asked to fill out symptom questionnaires and bladder diaries at regular intervals to monitor change. All treatment is free of charge, and patients who complete the trial will receive a small stipend.


Description:

Patients eligible for enrollment include:

- Age 18-65 years

- Symptomatic IC for at least six months

- Urinary frequency of at least eleven voids in a 24 hour period

- A self-rated global discomfort score of 4 or greater on a 0-10 scale

Patients may not be enrolled who have a history of chronic bladder disease or pelvic disease including cancer, calculi, infection or complications of nervous system disease or diabetes. They must be on no blood thinning agents or have had any recent medication changes or bladder procedures.

After screening physical examination and history-taking, patients will be asked to fill out standard symptom questionnaires. They will be given a bladder diary to fill out for the 24 hours prior to their first acupuncture treatment which will be scheduled within a week.

Patients will be asked to return from once- to twice-weekly for a total of twelve treatments. Patients will complete a bladder diary before each treatment and a questionnaire form before every other visit. The same questionnaire will be used at the exit interview after the last treatment, and a final time four weeks after the last treatment. This is because we are interested in the duration of potential benefit from acupuncture treatment.

Patients will be randomly assigned to one of two groups. All acupuncture will be performed through plastic shields so that the patient does not know which group he or she has been assigned to. In the first type of acupuncture, retractable needles are used such that the patient feels a pin sensation but there is no penetration of the epidermis. In the second type, non-retractable needles penetrate the acupuncture points into deeper tissue. It is not known whether deeper penetration is required for acupuncture to work, or if acupuncture is of benefit at all for this condition.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date September 2005
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Age 18-65 years

- Symptomatic IC for at least six months

- Urinary frequency of at least eleven voids in a 24 hour period

- A self-rated global discomfort score of 4 or greater on a 0-10 scale

Exclusion Criteria:

Medical History or Co-Morbid Conditions:

- Any history of: bladder calculus, tuberculous cystitis; neurological disease or diabetic cystopathy; malignant bladder tumors, urethral cancer

- Prior 3 years of uterine, cervical or vaginal cancer (women only)

- Prior 6-12 weeks of: bacterial urinary tract infection; active genital herpes; gross hematuria

- Concurrent active urethral calculus, ureteral calculus, symptomatic urethral diverticulum; documented chronic bacterial prostatitis (men only); active vaginitis, pregnancy (women only)

Prior and Concurrent Treatment for IC:

- Any history of: cyclophosphamide, pelvic radiation; augmentation cystoplasty, cystectomy or cystolysis, neurectomy, implanted peripheral nerve stimulator; prostate surgery or treatment (men only)

- In the prior 24 weeks: any treatment with intravesical BCG, cystocele, rectocele, urinary incontinence surgery, transvaginal surgery, hysterectomy, prolapse, vaginal delivery or C-section (women only)

- Prior 6-12 weeks: any treatment by urethral dilatation, cystometrogram, urodynamics, cystoscopy/hydrodistention, bladder biopsy; prostate biopsy (men only); any intravesical treatment other than BCG

- Prior 4 weeks: any new medications initiated for IC

- Concurrent intravesical heparin, chronic use of acetylsalicylic acid, non-steroidal anti-inflammatory drugs or opioid pain medications for another pain condition

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
Acupuncture


Locations

Country Name City State
United States University of Pennsylvania Pain Medicine Center Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
The Mary Elizabeth Groff Surgical Medical Research and Education Charitable Trust

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of improvement between arms as indicated by a Patient Overall Rating of Improvement Scale
Secondary Improvement in Interstitial Cystitis Symptom and Problem Indices (validated symptom-specific measures)
Secondary Improvement in University of Wisconsin-Interstitial Cystitis Scale (validated symptom-specific measure)
Secondary Improvement in frequency, urgency and nocturia as measured on bladder diaries
See also
  Status Clinical Trial Phase
Completed NCT04313972 - IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone Phase 4
Completed NCT03282318 - A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis Phase 2
Completed NCT03463499 - The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients N/A
Completed NCT02898220 - Trans-MAPP II Study of Urologic Chronic Pelvin Pain
Terminated NCT02591199 - Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Phase 2
Completed NCT02247557 - Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis Phase 2
Active, not recruiting NCT01731470 - Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS) N/A
Completed NCT01197261 - OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS) Phase 2
Completed NCT00971568 - Urinary Biomarkers Characteristic to Interstitial Cystitis N/A
Completed NCT00527917 - A Pilot Clinical Investigation of the Efficacy and Safety of Uracyst® Versus Placebo in Patients With Interstitial Cystitis/Painful Bladder Syndrome. Phase 2
Completed NCT00150488 - URACYST® For the Treatment of GAG Deficient Interstitial Cystitis N/A
Terminated NCT00086684 - Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis Phase 4
Recruiting NCT04845217 - Peppermint Oil for the Treatment of Interstitial Cystitis / Bladder Pain Syndrome Phase 1/Phase 2
Completed NCT04401176 - Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome Phase 2
Recruiting NCT05147779 - Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis Phase 1
Suspended NCT04450316 - Low-dose Naltrexone for Bladder Pain Syndrome Phase 2
Completed NCT04010513 - Hypnosis for Bladder Pain Syndrome N/A
Completed NCT05179460 - A Study of Pentosan Polysulfate Sodium and the Development of Pigmentary Maculopathy and Pigmentary Retinopathy
Completed NCT02232282 - Acupuncture for Female IC/PBSyndrome and Its Effect on the Urinary Microbiome: A Randomized Controlled Trial N/A
Completed NCT00546858 - Relationship of Interstitial Cystitis to Vulvodynia N/A